Women of child-bearing potential (WCBP) must agree to use a medically accepted form of pregnancy prevention for the duration of study treatment
Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, during the treatment portion of the study and for  months after completion of hetIL- administration.
Agree that during the trial, men will not father a child, and women cannot be or become pregnant. Participants must be of non-child bearing potential or agree to use one highly effective or combined contraceptive methods that result in a failure rate of <% per year during the treatment period and at least through week  after last dose;
For men and women of child-producing potential, the use of effective contraceptive methods during the study
Women of child bearing potential and men must agree to use contraception prior to study entry and through day  post HCT.
Women and men of child-producing potential must agree to use effective contraceptive methods during the study period (including post-treatment observation period)
For men and women of child-bearing potential, willing to use adequate contraception (e.g., latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study.
Patients must not be pregnant or nursing; women/men of reproductive potential must agree to use an effective contraceptive method during and for  months after completing protocol treatment; a negative pregnancy test is required within  days prior to registration for women of child-bearing potential
Women with child bearing potential and men with reproductive potential must be willing to practice acceptable methods of contraception
Pregnant and/or breast-feeding women, or patients (men and women) of child-producing potential not willing to use medically acceptable forms of contraception while on study treatment and for at least  months after study treatment. Pregnancy testing is not necessary for women who have had a hysterectomy or have not had a menstrual period for at least  consecutive months.
Women of child-bearing age and all men must use birth control of any type until at least  months after the last dose of therapy
Women of child bearing potential must not be pregnant or breastfeeding; a negative urine or blood pregnancy test must be obtained in women with child bearing potential on the day the prior to the first PET scan; men and women with reproductive potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) on study entry and for the duration of study participation
Women of child-bearing potential must agree to utilize a form of birth control or agree to undergo sexual abstinence during radiation therapy
Men and women of child-bearing age need to commit to using two methods of contraception simultaneously to avoid pregnancy.
Women of child-bearing potential must agree to use adequate contraceptive precautions (defined as oral contraceptives, intrauterine devices, surgical contraceptives, or combination of condom and spermicide) from the time of negative of the negative pregnancy test through the radiation treatment period
Subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through  days after the last dose of study therapy (for women of child-bearing potential) or  days after the last dose of study therapy (for men who have partners of child-bearing potential)
Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment
Women of child-bearing potential MUST have a negative serum or urine human chorionic gonadotropin (HCG) test unless prior hysterectomy or menopause (defined as  consecutive months of amenorrhea). Subjects should not become pregnant or breastfeed while on this study. Sexually active subjects must agree to use contraception for the duration of study participation and for  months after the last dose of neratinib and everolimus, palbociclib or trametinib.
Women of child-bearing potential (those who have had a menstrual cycle within the last year and have not had a tubal ligation or surgical removal of both ovaries and/or hysterectomy) must agree to abstain from vaginal intercourse and continue contraception for  weeks after discontinuation of study treatment
Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use highly effective methods of birth control that result in a low failure rate of less than % per year when used consistently and correctly prior to study entry, for the duration of study participation and for at least  weeks after treatment has ended
Women of child-bearing potential must agree to use  reliable methods of contraception beginning  weeks prior to the initiation of treatment, during therapy, and for at least  weeks after the last drug administration.
Women of child-bearing potential (WOCBP) must be willing to use acceptable means of birth control
A negative pregnancy test (if female of child bearing potential); for men and women of child-producing potential, willingness to use effective contraceptive methods during the study
For men and women of child-bearing potential, willing to use adequate contraception
Women of child bearing potential or sexually active fertile men with partners who are women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study and for up to  days after the last dose of investigational product
No pregnant or breastfeeding women; men or women of child bearing potential must agree to use an acceptable method of birth control (hormonal or barrier method of birth control; abstinence) to avoid pregnancy for at least  days after last study treatment (radiation or fresolimumab); all women of child bearing potential (last menstrual period within the previous  months and not surgically sterile) will be tested for pregnancy at pre-entry
Patients of child bearing potential or with partners of child-bearing potential must agree to practice recommended contraceptive methods to prevent pregnancy during treatment and for  months after the last dose of nivolumab for women, and  months after the last dose of nivolumab for men, and  months after the last dose of bevacizumab for subjects receiving bevacizumab
Men or women of childbearing potential who are unwilling to employ adequate contraception\r\n* NOTE: patients unwilling or unable to do any of the following are also excluded:\r\n** Men must agree to use a latex condom during sexual contact with a female of child-bearing potential even if they have had a successful vasectomy\r\n** Women of child bearing potential must agree to use  methods of reliable contraception simultaneously\r\n** All patients must be counseled at a minimum of every  days about pregnancy precautions and risks of fetal exposure
Sexually active women of child-bearing potential must agree to use two forms of contraception prior to study entry and for the duration of study participation. A pregnancy test is required prior to study enrollment and monthly while on treatment with indoximod for all women of child- bearing potential. Also men should be discouraged from fathering children while on treatment.
Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential
Men and women of child-bearing potential must agree to use effective birth control or abstinence during and for a period of  months after the last vaccination therapy
Pregnant or lactating women. Women of childbearing potential must have a urine pregnancy test proven negative within  days prior to randomization. Men and women of child-bearing potential must agree to use adequate contraception.
If of child-bearing potential (< one year post-menopausal), must agree to practice an effective method of avoiding pregnancy (including oral or implanted contraceptives, intrauterine device, condom, diaphragm with spermicidal, cervical cap, abstinence or sterile sex partner) from the time informed consent is signed (women only) or the time of initiation of sunitinib (sunitinib malate) (men only); both men and women must agree to continue using such precautions while receiving sunitinib or valproic acid and for  days after the final dose
Women and men of child producing potential must agree to use highly effective means of contraception during study participation, and for at least  days after the last administration of study medication.
Women of child bearing potential must agree to use birth control for the duration of the study
Eligibility criteria specific to the CC- arm:\r\n* Participants must be willing and able to provide written informed consent for the CC- arm of the INSIGhT trial\r\n* Women of child bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from date of initial dose and for  days following the last dose of CC-; men (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in sexual activity with a woman of child bearing potential from date of initial dose and for  days following the last dose of CC-
Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice  highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child (a) while receiving treatment of guadecitabine, decitabine, or azacitidine and for at least  months after completing treatment and (b) while receiving treatment with high-intensity TC or LDAC and for at least  months after completing treatment.
Women who are pregnant or lactating are ineligible; women who are of child-bearing potential need to practice effective methods of contraception including oral contraceptives, intrauterine device, diaphragm with spermicides, and/or abstinence
Women of child-bearing potential must not be pregnant and must have a negative pregnancy test; men and women must agree to practice effective contraception while on this study
Women of child-bearing potential and men must agree to use adequate contraception prior to the start of treatment, for the duration of treatment, and for  months after last dose of study treatment
For men and women of child-bearing potential, willing to use adequate contraception (i.e., latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study.
For men and women of child-producing potential, use of effective contraceptive methods during the study
Pregnant women or women who are of child bearing age who are not willing to use two () forms of contraception during treatment with enzalutamide and for six () months after treatment
FOR PDX-GUIDED THERAPY THROUGH ONGOING TRIALS AT MD ANDERSON OR OFF-PROTOCOL WITH STANDARD OF CARE (PART ): Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. Men must agree not to father a child and agree to use a condom if his partner is of child-bearing potential.
Women of child bearing potential and men must agree to remain abstinent or use adequate contraception (failure rate < %) for the duration of study and for  days after the completion of the therapy
Pregnant women are excluded from this study; breastfeeding should be discontinued; women of child-bearing potential must agree to use adequate birth control throughout the study duration
If of child-bearing potential, patient agrees to use adequate birth control measures during study participation
If the subject is female and of child-bearing potential, subject must have negative serum or urine pregnancy test within  days of treatment with research agent; men with partners of child-bearing potential and women of child-bearing potential must be willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm and continue this for one year post HSPC infusion
Women of child bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for  months thereafter
If the subject is female and of child bearing potential, subject must have negative serum or urine pregnancy test within  days of treatment with research agent; men with partners of child-bearing potential and women of child-bearing potential must be willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm and continue this for one year post HSPC infusion
Women of child-bearing potential must agree to use adequate contraception, defined as complete abstinence from intercourse with men or two methods
Female participants must have a negative pregnancy test within  days of entering into the study; both men and women of child bearing potential must agree to use adequate methods of contraception for the duration of the treatment; women must avoid pregnancy, and men must avoid fathering children while in the study and for  months following the last study drug treatment
Women of child-bearing potential and men must use an acceptable method of contraception during treatment and for  weeks after treatment for women and  weeks for men
If the subject is a woman of child-bearing potential or man who is sexually active with woman of child-bearing potential, the subject agrees to use adequate contraception from signing of the ICF, for the duration of study participation; and for  weeks after the last dose of IMP for women or  weeks after the last dose of IMP for men;
Women of child-bearing potential and men must use an acceptable method of contraception during treatment and for  weeks after treatment for women and  weeks for men
For women of child-bearing potential and for men with partners of child-bearing potential, subject must agree to take contraceptive measures for duration of treatments and  months after the last dose of BEV.
Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least  consecutive months if ? years or  months if > years, must have a negative serum pregnancy test within four weeks prior to the first dose of study drug and must agree to use adequate methods of birth control throughout the study. Adequate methods of contraception are outlined in the protocol.
Women of child-bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for  months thereafter
men and women must agree to the use an effective method of contraception during the study and for at least  months post last dose of study drug administration. Women of child-bearing potential must have negative serum and urine pregnancy tests at screening and during each treatment cycle, respectively
Women of child bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for  months thereafter
Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study (see below)
Men and women of child bearing potential must agree to use adequate birth control throughout their participation in the study and for  days following the last study treatment.
Men who are sexually active with women of child bearing potential must agree to use a condom from screening through  months after the last dose of study treatment (including nivolumab single agent).
Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential
Women of child bearing potential and men must agree to use adequate contraception during the study and for  months after their last dose of study drug.
Women of child-bearing potential and their partners must agree to use contraception (hormonal or barrier method of birth control; abstinence) from study entry until  days after last dose of study drug; male partners should be instructed to use contraception during the study period; women of child-bearing potential (intact uterus) should have a negative serum pregnancy test; if a woman becomes pregnant or suspects she is pregnant while on study, she should tell her treating physician immediately; female patients must have evidence of non-child-bearing potential by fulfilling  of the following at screening: a) post-menopausal defined as >  years old and amenorrheic for >=  consecutive months following cessation of all exogenous hormonal treatments; b) documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation
Pregnant women are excluded; we recommend that women of child-bearing potential use an acceptable method of birth control to avoid pregnancy for  months following stereotactic radiosurgery and that male subjects use effective contraception for the same period
Women of childbearing potential must have a negative serum or urine pregnancy test within  days and will also need to use contraceptives; men must agree not to father a child and agree to use a condom if his partner is of child bearing potential
Women of child bearing potential must have a negative pregnancy test within  days prior to study registration and agree to use adequate birth control during study treatment
Women with child bearing potential and men with reproductive potential must be willing to practice acceptable methods of contraception
Women of child bearing potential (WCBP), must agree to use  contraceptive methods
Women of child-bearing potential and men must agree to use adequate contraception
Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least  months after treatment has ended.
Women of child-bearing potential and men must agree to use adequate contraception
Women of child bearing potential must have a negative pregnancy test within  days prior to study registration and agree to use adequate birth control during study treatment
Use of effective contraceptive methods if men and women of child producing potential
Use of effective contraceptive methods if men and women of child producing potential
Pregnancy: Women of child-bearing potential and men must agree to use contraception prior to study entry and for the duration of study participation; a woman of child-bearing potential is defined as a woman who has not been naturally post-menopausal for at least  consecutive months or with no previous surgical sterilization; a negative pregnancy test result will be required before any study drug is given
Women who are pregnant or lactating are ineligible due to teratogenic effects on developing fetuses; women who are of child-bearing potential need to practice effective methods of contraception including oral contraceptives, intrauterine device, diaphragm with spermicides, and/or abstinence
Men and women of child bearing potential must agree to use adequate birth control throughout their participation in the study and for  days following the last study treatment.
Women of child-bearing potential and men must agree to use adequate contraception.
Women must be either of non-child bearing potential, or women with child-bearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study
Women who are pregnant or lactating, as well as women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the duration of the study
For men and women of child-producing potential, use of effective barrier contraceptive methods during the study and for one month following study product injections
Women of child-bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for  months thereafter
Women of childbearing potential must have a negative serum or urine pregnancy test within  days and must agree to practice acceptable contraceptive methods; men must agree not to father a child and agree to use a condom if his partner is of child bearing potential
For men and women of child-producing potential - willingness to employ appropriate contraceptive methods (including abstinence) during the study.
Women must be either of non-childbearing potential or women with child-bearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study.
Women of childbearing potential must have a negative serum or urine pregnancy test within  days; men must agree not to father a child and agree to use a condom if his partner is of child bearing potential
Females of childbearing potential must have a negative pregnancy test within  hours prior to initiation of protocol therapy; NOTE: subjects are considered not of child bearing potential if they are surgically sterile, they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy or they are postmenopausal; menopause is the age associated with complete cessation of menstrual cycles, menses, and implies the loss of reproductive potential; by a practical definition, it assumes menopause after  year without menses with an appropriate clinical profile at the appropriate age; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time the consent is signed and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; women of child-bearing potential and men treated or enrolled on this protocol must also agree to use adequate contraception (hormonal or barrier method of birth control; abstinence)  months after completion of rhIL
Women of childbearing potential must have a negative serum or urine pregnancy test within  days and will also need to use contraceptives; men must agree not to father a child and agree to use a condom if his partner is of child bearing potential
Women of child-bearing potential must have a negative pregnancy test within  days of initiation of dosing and must agree to use two acceptable methods of birth control while on study drug and for  months after the last dose. Women of non-childbearing potential may be included if they meet at least one of the following criteria:
Women of child-bearing potential and men must agree to use adequate contraception
Women of child-bearing potential must agree to utilize a form of birth control or agree to undergo sexual abstinence during radiation therapy
Women of child bearing potential must have a documented negative pregnancy test within  weeks prior to day  of treatment and agree to use a non-hormonal form of birth control during the duration of the trial therapy
Patients of child bearing potential or with partners of child-bearing potential must agree to practice recommended contraceptive methods to prevent pregnancy during treatment and for  month after the last dose of AED for women and men
Women of child-bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for  months thereafter
Women of child-bearing potential must agree to use adequate contraceptive precautions (defined as oral contraceptives, intrauterine devices, surgical contraceptives or a combination of condom and spermicide) from the time of negative pregnancy test through completion of the radiation treatment period
Women of child bearing potential must not be pregnant or breastfeeding; a negative serum pregnancy test must be obtained in women with child bearing potential within  days of the first PET scan; men and women with reproductive potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) on study entry and for the duration of study participation; on the day of the scan the staff will verify and record that the patient has not had unprotected intercourse and does not think that she is pregnant; a repeat serum pregnancy test will be done if the patient cant verify this
Female patients undergoing optional F-MISO-PET scan cannot be pregnant or nursing, as confirmed by serum pregnancy test if the patient is a woman of child-bearing potential; females of child-bearing potential are defined according to Food and Drug Administration (FDA) guidelines as women capable of becoming pregnant, including women on oral injectable or mechanical contraception, women who are single, women whose husbands have been vasectomized, or women whose husbands have received or are utilizing mechanical contraceptive devices; if the result of the pregnancy test is positive, the patient (female) will be withdrawn from the study prior to administration of study treatment
Women of child-bearing potential and their partners must agree to use contraception (hormonal or barrier method of birth control; abstinence) from the time of study entry until  days after the last dose of study medication; women of child-bearing potential (intact uterus) should have a negative serum pregnancy test; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; female patients must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:\r\n* Post-menopausal defined as aged more than  years and amenorrheic for at least  consecutive months following cessation of all exogenous hormonal treatments\r\n* Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation; male partners should be instructed to use contraception during the study period
For women of child-bearing potential and for men with partners of child-bearing potential, patient must agree to take contraceptive measures for duration of treatments and for one month after last study treatment
